MedSpeed To Provide Transportation Logistics To Sequenom Center For Molecular Medicine
FOR IMMEDIATE RELEASE
Contact: Lynn Jensen
VP, Marketing & Business Development
(630) 335-9892
[email protected]
MEDSPEED TO PROVIDE TRANSPORTATION LOGISTICS TO SEQUENOM
CENTER FOR MOLECULAR MEDICINE
-Leading Healthcare Logistics Company Partners with Laboratory
Science Innovator-
Elmhurst, IL, September 18, 2009 - MedSpeed LLC,
a leading provider of integrated transportation services to the
healthcare industry, announced today that it has partnered with
Sequenom Center for Molecular Medicine, LLC (Sequenom CMM) to
manage and execute its national transportation services.
Headquartered in Grand Rapids, Michigan, Sequenom CMM is a
next-generation CLIA (Clinical Laboratory Improvement Amendments,
1988) molecular diagnostic laboratory and a wholly-owned subsidiary
of Sequenom, Inc. (NASDAQ: SQNM).
Faced with the demands of launching its service offering on a
national scale, Sequenom CMM chose to work with MedSpeed to give it
turnkey access to a comprehensive, customer centric logistics
operation. "Partnering with MedSpeed immediately provides our
laboratory with a flexible, top quality service offering at an
affordable cost," said Howard Slutsky, senior director of
operations at Sequenom CMM. "And, because MedSpeed's operation is
seamlessly scalable, we can focus on building our business knowing
that our logistics function will accommodate our growth."
To support Sequenom CMM, MedSpeed bolstered its corporate-based
dispatch and analytical capacities as well as expanded its
operational reach. Working collaboratively with Sequenom CMM,
MedSpeed tailored these and other elements of its service solution
to match Sequenom CMM's current and future needs.
"We are delighted to be working with Sequenom CMM," said Jake
Crampton, CEO, MedSpeed. "Sequenom CMM is not only a thought and
technology leader in life sciences, its operational needs for
commercialization also support MedSpeed's establishment of a
national footprint."
About MedSpeed:
MedSpeed is an innovative provider of transportation services
exclusively to the healthcare industry. MedSpeed designs and
executes centralized transportation outsourcing solutions for
integrated healthcare delivery networks, independent clinical
laboratories, blood banks, and institutional pharmacies. ISO
certified and guided by the principles of Lean Six Sigma, MedSpeed
helps its healthcare customers improve and standardize service,
reduce costs and focus on core goals. For more information, visit
www.medspeed.com.
About Sequenom Center for Molecular
Medicine
In 2008, Sequenom acquired a CAP accredited and CLIA-certified
molecular diagnostic laboratory located in Grand Rapids, Mich. and
named it the Sequenom Center for Molecular Medicine. Through this
laboratory, the company plans to develop and commercialize a full
range of cutting-edge diagnostic tests intended for physicians and
that focus on women's health. In addition to the recently launched
SensiGene Cystic Fibrosis Carrier Screening test, Sequenom CMM is
also developing noninvasive prenatal tests using a technology that
derives fetal information from a maternal blood sample; the planned
menu includes tests for fetal RHD genotyping, Fetal(xy) (fetal sex
determination), trisomy 21, and others. For more information please
visit http://www.scmmlab.com.
Sequenom Forward-Looking Statements
Except for the historical information contained herein, the
matters set forth in this press release, including statements
regarding Sequenom CMM building its business, its growth, the
Company's plans through Sequenom CMM to develop and commercialize a
full range of cutting-edge diagnostic tests including noninvasive
prenatal tests and a planned menu of tests including tests for
fetal RHD genotyping, Fetalxy fetal sex determination, trisomy 21,
and others, are forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to
risks and uncertainties that may cause actual results to differ
materially, including the risks and uncertainties associated with
the Company's ability to develop and commercialize new technologies
and products, particularly new technologies such as noninvasive
prenatal and other diagnostics and laboratory developed tests,
reliance upon the collaborative efforts of other parties, the
Company's ability to manage its existing cash resources or raise
additional cash resources, competition, intellectual property
protection and intellectual property rights of others, government
regulation particularly with respect to diagnostic products and
laboratory developed tests, obtaining or maintaining regulatory
approvals and other risks detailed from time to time in the
Company's Annual Report on Form 10-K for the year ended December
31, 2008 and other documents subsequently filed with or furnished
to the Securities and Exchange Commission. These forward-looking
statements are based on current information that may change and you
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
All forward-looking statements are qualified in their entirety by
this cautionary statement, and the Company undertakes no obligation
to revise or update any forward-looking statement to reflect events
or circumstances after the issuance of this press release.